Answers are grounded in this paper and cite their sources.
In mice and humans with cancer, intravenous ¹³C-glucose infusion results in ¹³C labeling of tumor tricarboxylic acid (TCA) cycle intermediates, indicating that pyruvate oxidation in the TCA cycle occurs in tumors. The TCA cycle is usually coupled to the electron transport chain (ETC) because NADH generated by the cycle is reoxidized to NAD⁺ by the ETC. However, ¹³C labeling does not directly report ETC activity, and other pathways can oxidize NADH, so the ETC's role in these labeling patterns is unverified. We examined the impact of the ETC complex I inhibitor IACS-010759 on tumor ¹³C labeling. IACS-010759 suppresses TCA cycle labeling from glucose or lactate and increases labeling from glutamine. Cancer cells expressing yeast NADH dehydrogenase-1, which recycles NADH to NAD⁺ independently of complex I, display normalized labeling when complex I is inhibited, indicating that cancer cell ETC activity regulates TCA cycle metabolism and ¹³C labeling from multiple nutrients.
No takes yet. Share an insight, caveat, or question.
Pachnis et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: